Hims & Hers continues growing rapidly, but shrinking margins and rising costs are beginning to test the company's long-term profitability story.
We use Google Analytics to count anonymous page views and understand which content gets read. No ads, no profiles. Decline keeps you on cookieless mode. Details.
Uniquement les titres à fort signal — événements macro, résultats, M&A, régulation. Listicles et clickbait d'analystes filtrés par défaut. Rafraîchi toutes les heures.
Hims & Hers continues growing rapidly, but shrinking margins and rising costs are beginning to test the company's long-term profitability story.
HIMS reports an adjusted loss and a revenue miss in first-quarter 2026 as gross margin decreases, but it lifts its full-year revenue outlook.
Hims & Hers (NYSE:HIMS) reported first quarter financial results that included a wider-than-expected loss and softer revenue performance, sending shares down nearly 14% to about $25 on Tuesday morning. For the quarter, the telehealth company posted a net loss of $92.1 million, or $0.40...
Hims & Hers stock sinks as higher costs weighed on the health platform's quarterly results.
Hims & Hers stock sinks as higher costs weighed on the health platform's quarterly results.
By Amina Niasse and Siddhi Mahatole May 11 (Reuters) - Hims & Hers Health missed Wall Street estimates for first-quarter revenue and posted a surprise loss on Monday, as the telehealth company's shift